Metamizol Sodic Sopharma

Metamizole sodium, the active ingredient in Metamizol Sodic Sopharma, is a pyrazolone presented as an injectable solution for intramuscular and intravenous use. It is employed to relieve moderate to severe pain, reduce fever, and provide postoperative analgesia, including treatment of colic.

GNH USA supplies Metamizol Sodic Sopharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is distributed under strict regulatory oversight.

Metamizole sodium is used in clinical settings to manage pain and fever through its analgesic and antipyretic actions.

Pain: provides rapid relief of moderate to severe acute pain Fever: reduces elevated body temperature in febrile states Postoperative analgesia: controls pain after surgical procedures Colic: alleviates visceral pain associated with intestinal colic

Metamizole sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Nausea: transient feeling of queasiness. - Vomiting: occasional episodes. - Dizziness: light‑headed sensation. - Hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, potentially life‑threatening. - Anaphylaxis: acute allergic reaction with respiratory compromise. - Stevens‑Johnson syndrome: severe skin and mucous membrane disorder. - Hemolytic anemia: destruction of red blood cells. - Severe liver dysfunction: marked elevation of hepatic enzymes.

When using Metamizole sodium, clinicians should observe specific safety measures.

Assess blood counts: perform baseline and periodic complete blood count to monitor for agranulocytosis. Avoid in known hypersensitivity: discontinue if allergic reactions occur. Use caution in renal impairment: adjust monitoring as drug is renally excreted. Limit duration: avoid prolonged use without medical supervision. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Metamizole sodium can interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive agents: increased risk of agranulocytosis. - Combination with sulfonamides: heightened potential for severe blood dyscrasias. - Co‑administration with anticoagulants: may potentiate bleeding risk. - Use with other NSAIDs: additive gastrointestinal toxicity. - Interaction with CYP450 inhibitors: possible altered metabolism.

Moderate Interactions (Monitor Closely): - Concomitant antihypertensives: may enhance hypotensive effect. - Use with diuretics: monitor electrolyte balance. - Combination with other antipyretics: assess cumulative fever reduction. - Co‑administration with drugs affecting platelet function: monitor bleeding. - Interaction with immunosuppressants: observe for infection risk.